Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Mutations in the targets of designer drugs critically influence their effectiveness

Mutations in the targets of designer drugs critically influence their effectiveness

Researchers identify protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with gefitinib

Researchers identify protein called EMP-1 that is present in the tumors of patients who fail to respond to treatment with gefitinib

AstraZeneca announces U.S. labeling change to Iressa (gefitinib tablets)

AstraZeneca announces U.S. labeling change to Iressa (gefitinib tablets)

Study examines biomarkers for response to erlotinib in glioma

Study examines biomarkers for response to erlotinib in glioma

New drug combination prevents breast cancer growth pre-surgery

New drug combination prevents breast cancer growth pre-surgery

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Study shows the longest reported survival rate for patients with locally advanced lung cancer

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Researchers find ovarian cancer patients who appear to respond better than others to gefitinib, or Iressa

Clinical trial of gefitinib for advanced lung cancer closes early

Clinical trial of gefitinib for advanced lung cancer closes early

Study describes the first known mutation to occur in lung cancer patients who have never smoked

Study describes the first known mutation to occur in lung cancer patients who have never smoked

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Blocking estrogen may be vitally important to improving survival from lung cancer

Blocking estrogen may be vitally important to improving survival from lung cancer

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

Mutation of a gene involved in non-small cell lung cancer linked to drug effectiveness

Mutation of a gene involved in non-small cell lung cancer linked to drug effectiveness